However, even though the IGF-1R targeting antibodies AMG-479, IMC-A12 (cixutumumab) and TKI NVP-AEW541 have been shown to reduce tumor proliferation in pancreatic [113], breast cancer [131] and endometrial cancer [132,133] cells in preclinical models, they are likely ineffective as monotherapies. This evidence concerns the gene IGF1R and neoplasm.